SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

Rein Therapeutics publishes LTI-03 presentation, Phase 2 trial enrolling

Rein Therapeutics published an LTI-03 presentation citing Phase 1b biomarker activity, preclinical antifibrotic data and that the RENEW Phase 2 trial is now enrolling.

RNTX

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.

Related stories